MARKET

CSBR

CSBR

Champions
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.83
+0.11
+1.26%
After Hours: 8.83 0 0.00% 16:00 10/29 EDT
OPEN
8.70
PREV CLOSE
8.72
HIGH
8.87
LOW
8.70
VOLUME
9.11K
TURNOVER
--
52 WEEK HIGH
10.89
52 WEEK LOW
4.020
MARKET CAP
112.39M
P/E (TTM)
-83.1450
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Champions Oncology, Inc. Just Beat Revenue Estimates By 11%
Shareholders of Champions Oncology, Inc. (NASDAQ:CSBR) will be pleased this week, given that the stock price is up 11...
Simply Wall St. · 09/16 12:27
Champions Oncology +9.8% on FQ1 earnings beat
Champions Oncology ([[CSBR]] +9.8%) records FQ1 revenue of $9.5M, an increase of 42% Y/Y.The increase in revenue was due to increased sales, both in number and size of studies, and strong
Seekingalpha · 09/15 16:03
Champions Oncology EPS beats by $0.01, beats on revenue
Champions Oncology (CSBR): FQ1 Non-GAAP EPS of $0.02 beats by $0.01; GAAP EPS of $0.01.Revenue of $9.55M (+41.7% Y/Y) beats by $0.94M.Press Release
Seekingalpha · 09/14 20:03
Champions Oncology Reports Record Quarterly Revenue of $9.5 Million
HACKENSACK, NJ / ACCESSWIRE / September 14, 2020 / Champions Oncology, Inc.
ACCESSWIRE · 09/14 20:00
The Week Ahead In Biotech: Decision Day For Bausch Health, IPO Flow Resumes, Oncology Conference
Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market.
Benzinga · 09/13 13:49
Champions Oncology to Announce First Quarter Financial Results on Monday, September 14, 2020
HACKENSACK, NJ / ACCESSWIRE / September 8, 2020 / Champions Oncology, Inc.
ACCESSWIRE · 09/08 21:30
Champions Oncology slumps on Q4 reports
Seeking Alpha · 07/28 19:38
Champions Oncology, Inc. (CSBR) CEO Ronnie Morris on Q4 2020 Results - Earnings Call Transcript
Seeking Alpha · 07/27 23:24
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CSBR. Analyze the recent business situations of Champions through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CSBR stock price target is 11.00 with a high estimate of 12.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 63
Institutional Holdings: 7.47M
% Owned: 58.73%
Shares Outstanding: 12.73M
TypeInstitutionsShares
Increased
17
583.83K
New
20
331.36K
Decreased
5
392.12K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.04%
Pharmaceuticals & Medical Research
+0.17%
Key Executives
Chairman/Director
Joel Ackerman
Chief Executive Officer/Director
Ronnie Morris
Chief Financial Officer
David Miller
Lead Director/Independent Director
David Sidransky
Independent Director
Philip Breitfeld
Independent Director
Daniel Mendelson
Independent Director
Abba Poliakoff
Independent Director
Scott Tobin
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CSBR
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Translational Oncology Solutions (TOS) and Personalized Oncology Solutions (POS). The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using TumorGraft studies. POS assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The Company subsidiaries include Champions Oncology (Israel) and Limited and Champions Biotechnology U.K., Limited.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Champions Oncology Inc stock information, including NASDAQ:CSBR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CSBR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CSBR stock methods without spending real money on the virtual paper trading platform.